NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) ("KALA" or the "Company") today announced that Yenvy Truong, founder of The LSM Group, has joined the Company's advisory team. Ms. Truong will support management as KALA grows its existing business and evaluates opportunities to expand it, including through acquisitions.

Ms. Truong has spent roughly two decades in healthcare operations, including building and operating diagnostic laboratories. She has founded, scaled, and advised healthcare and life sciences companies across genomics, longevity, remote patient monitoring, digital musculoskeletal care, and metabolic medicine, through mergers, acquisitions, and growth financings totaling more than $200 million in transaction and enterprise value.

KALA is focused on expanding its business in diagnostics, genetic testing, and other areas of preventive and connected health, all enhanced by AI. That growth may come from the Company's existing business, commercial agreements such as its exclusive distribution and reseller agreement with Virotek Inc., new services, and acquisitions. The Company believes Ms. Truong's operating experience and industry relationships will provide it with insight into opportunities that align with those goals.

"Our focus is growth, starting with the business and agreements we already have," said Avi Minkowitz, Chief Executive Officer of KALA. "Acquisitions can add to that, but only when they fit. Yenvy has built and run diagnostics and biotech/healthcare businesses and understands what it takes to scale them. She gives us a clearer view of where the right opportunities are, whether that is a new service, a new partner, or a company we bring into KALA."

"KALA has a clear plan to grow its business and to expand where it makes sense. I'm looking forward to working with Avi and the team to identify opportunities that fit that plan and to help build long-term value," said Ms. Truong.

Ms. Truong serves as an advisor to the Company and is neither an officer nor an employee of KALA.

About Kala Bio, Inc. (NASDAQ:KALA)

KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company's dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and Researgency.ai

About The LSM Group

The LSM Group is a healthcare advisory firm working at the intersection of healthcare, life sciences, AI, and capital strategy. Founded by Yenvy Truong, the firm advises investors and operators on diagnostics, specialty pharmaceutical assets, applied AI in regulated environments, and longevity, and maintains a domain expert panel that evaluates companies before capital is committed.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategic initiative to build an AI infrastructure platform for the biotechnology industry; plans to develop and deploy the Researgency AI platform both internally and to external clients; expectations regarding the potential benefits of AI-driven analytical tools; plans to reassess historical datasets and identify new therapeutic indications; expectations regarding the AI drug discovery market and industry trends; expectations regarding the Company's ability to generate recurring platform revenue; plans regarding potential partnerships, client deployments, or technology licensing opportunities; expectations regarding the Company's competitive position and the differentiation of its on-premises deployment model; the potential exercise of development continuation or renewal options under the Agreement; and other statements that are not historical facts. It also includes statements regarding the proposed distribution partnership with Virotek, including the negotiation and execution of definitive agreements and the anticipated benefits and timing thereof.

The Company used words like "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from those expressed or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment, and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients; risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company's product candidates may not be successfully developed or commercialized; risks related to the Company's limited cash resources and ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it was published and/or does not accurately predict the future; risks related to the Company's ability to raise future capital and the possibility that market conditions may limit the Company's ability to raise capital on favorable terms; risks related to the Company's ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers; the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the Agreement; and other risks detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K as they may be revised in the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Avi Minkowitz

Chief Executive Officer, KALA BIO, Inc.

am@kalarx.com

www.kalarx.com | www.Researgency.ai